The Preoperative AST/ALT (De Ritis) Ratio Represents a Poor Prognostic Factor in a Cohort of Patients with Nonmetastatic Renal Cell Carcinoma
- 1 July 2015
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 194 (1), 30-35
- https://doi.org/10.1016/j.juro.2015.01.083
Abstract
Aminotransaminases, which are strongly involved in cellular metabolism and cancer cell turnover, represent easily measureable, potential blood based biomarkers. We evaluated the prognostic value of the preoperatively assessed AST/ALT (De Ritis) ratio on clinically meaningful end points in a large European cohort of patients with nonmetastatic renal cell carcinoma. We retrospectively evaluated clinicopathological data on 698 patients with nonmetastatic renal cell carcinoma operated on between 2005 and 2013 at a single tertiary academic center. The potential prognostic value of the AST/ALT ratio was analyzed using the Kaplan-Meier method, and univariate and multivariate Cox proportional regression models. The impact of the ratio on the predictive accuracy of the Leibovich prognosis score was determined by the Harrell c-index. An increased (1.26 or greater) preoperative AST/ALT ratio was statistically significantly associated with several well established prognostic factors, including pathological T stage, as well as with histological tumor necrosis (p <0.05). On multivariate analysis an increased preoperative AST/ALT ratio was an independent prognostic factor for metastasis-free survival (HR 1.61, 95% CI 1.25-2.07, p <0.001) and overall survival (HR 1.76, 95% CI 1.34-2.32, p <0.001). The Harrell c-index was 0.77 using the Leibovich prognosis score and 0.81 when AST/ALT was added. In our study cohort with nonmetastatic renal cell carcinoma the preoperatively assessed AST/ALT ratio represented an independent prognostic factor. This ratio might further improve the predictive accuracy of well established prognosis scores.Keywords
This publication has 29 references indexed in Scilit:
- Adjuvant Therapy for Renal Cell CarcinomaClinical Genitourinary Cancer, 2014
- High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patientsBritish Journal of Cancer, 2013
- Renal cell carcinoma stage migration in a single European centre over 25 years: effects on 5- and 10-year metastasis-free survivalInternational Urology and Nephrology, 2012
- Population Based Analysis of the Increasing Incidence of Kidney Cancer in the United States: Evaluation of Age Specific Trends From 1975 to 2006Journal of Urology, 2012
- External Validation of the Leibovich Prognosis Score for Nonmetastatic Clear Cell Renal Cell Carcinoma at a Single European Center Applying Routine PathologyJournal of Urology, 2011
- Age-Adjusted Incidence, Mortality, and Survival Rates of Stage-Specific Renal Cell Carcinoma in North America: A Trend AnalysisEuropean Urology, 2010
- Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomyCancer, 2005
- Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinomaCancer, 2003
- Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinomaCancer, 2003
- An overview of prognostic factors in small cell lung cancerBritish Journal of Cancer, 1990